Consortium consisting of Nordic Capital and Permira receives final regulatory approval in respect of its takeover offer to the shareholders of Bavarian Nordic

Core Viewpoint - Innosera ApS has received all necessary regulatory approvals from the European Commission for its all-cash voluntary recommended public takeover offer for Bavarian Nordic A/S, with the offer period set to expire on 14 October 2025 [1][27]. Group 1: Offer Details - The offer is contingent upon the minimum acceptance condition of 75% of the shares in Bavarian Nordic, excluding treasury shares [2]. - If the remaining conditions are satisfied by the expiration date, the completion of the offer is expected to occur in mid-November 2025 [4]. - Bavarian Nordic shareholders are encouraged to accept the offer before the expiration date [3]. Group 2: Company Background - Bavarian Nordic is a global vaccine company focused on improving health through innovative vaccines, including mpox and smallpox vaccines [8].